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• Twelve adult female P rats
• EtOH acclimation (3 days): water was removed from the home cage and rats were given a bottle of 20% EtOH.
• Phase 1 & 2. Half the rats received naltrexone treatments during Phase 1, and half received treatments during Phase 2.
In the EtOH-alone phase, naltrexone did not have any significant effect on EtOH or
water consumption. However, in the co-use phase, naltrexone dose-dependently
reduced EtOH consumption; water consumption was also reduced, but only at the
highest dose (0.6 mg/kg). Also, in the co-use phase, naltrexone significantly reduced
inactive lever presses for nicotine at the lowest dose (0.15 mg/kg), but it had no effect
on active lever presses for nicotine. Thus, naltrexone is more effective in treating EtOH
use when tested in combination with nicotine rather than when tested alone.
The present study used concurrent access to EtOH and nicotine, which has been used
in very few previous studies. It also measured choice for water (natural reward) and
inactive lever presses (non-reinforced behavior) to determine if naltrexone had any
effect on those behaviors. Because the highest dose of naltrexone (0.6 mg/kg) reduced
water drinking, we did not increase the test dose beyond that point. Further research
must be conducted to find medications to treat the co-use of EtOH and nicotine.
Future studies may involve counterbalancing the order in which EtOH alone and
EtOH+nicotine co-use phases are administered. In addition, a higher FR schedule of
nicotine could be used (the highest ratio in the present study was FR30). A higher or
lower dose of nicotine could also be used, or multiple doses could be used, in order to
determine if naltrexone would have significant effects on active lever presses. Finally,
male P rats could be used as the test subjects in order to account for possible sex
differences.
According to the National Institutes on Health, although underage drinking and binge
drinking have declined in the past decade, alcohol (EtOH) is still the most commonly
abused substance in the United States (NCAAD, 2015) and worldwide (Falk et al., 2016).
In addition, approximately 80% of people with an EtOH use disorder also use tobacco,
which equates to more than 46 million co-abusers of EtOH and nicotine in the United
States (Miller & Gold, 2008). Furthermore, the co-use of EtOH and nicotine increases the
difficulty of cessation of either substance (McKee & Weinberg, 2013). However, there is
currently no single medication to treat the co-abuse of EtOH and nicotine, despite the
two substances having similar mechanisms of action.
The objective of the present study was to determine the effectiveness of the opioid
antagonist naltrexone at reducing the consumption of EtOH and nicotine in female
alcohol-preferring (P) rats. P rats have been selectively bred to have a genetic
predisposition for alcohol abuse, which allows them to be used as an animal model of
alcoholism. P rats readily self-administer i.v nicotine (Le et al., 2016), have EtOH
consumption during adolescence that is similar to that seen in adulthood, and operantly
respond for EtOH until they are impaired/intoxicated (Bell et al., 2006). Thus, P rats are a
useful model for studying naltrexone’s effects on EtOH and nicotine co-use.
Naltrexone has been FDA approved for alcohol use disorder based on its ability to
treat alcohol dependence. Animal studies have shown that naltrexone decreases nicotine
self-administration in rats (Ismayilova & Shoaib, 2010; Guy et al., 2014). In addition,
naltrexone reduces EtOH self-administration in rats (Williams & Broadbridge, 2009) and
also reduces EtOH self-administration in rats given alternating access to either EtOH or
nicotine (Le et al., 2014). These findings indicate that naltrexone has the potential to
reduce the co-use of EtOH and nicotine.
Modified Operant Chamber
• Allowed rats concurrent access to i.v. nicotine (0.03 mg/kg/infusion) and oral EtOH
and water (0 vs 15% EtOH).
• Pressing the active lever provided rats with nicotine through a headmount/catheter
connected to the jugular vein.
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In Phase 1 (EtOH alone), naltrexone did not have any significant effect on EtOH
consumption or on water consumption (Figure 1 and 2). However, in Phase 2, naltrexone
significantly reduced EtOH consumption at all three naltrexone doses tested (0.15, 0.3, and
0.6 mg/kg), F(3, 18) = 1.57, p < 0.05 when compared to the vehicle control (Figure 3). In
addition, naltrexone significantly reduced water consumption in Phase 2 but only at the
highest dose tested (0.6 mg/kg), F(3, 18) = 5.65, p < 0.05 (Figure 4). Also in Phase 2,
naltrexone did not have any significant effect on active lever presses for nicotine (Figure 5).
However, it did significantly reduce inactive lever presses for nicotine at the lowest dose
tested (0.15 mg/kg), F(3, 18) = 3.38, p < 0.05 when compared to the vehicle control (Figure
6).
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